GUFICBIOPharmaceuticals
Gufic Biosciences Ltd — Cash Flow Statement
₹273.80
-4.82%
Gufic Biosciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Sale Of PPE | 4.77 Cr | 4.57 Cr | 0.03 Cr | 0.07 Cr | — |
| Free Cash Flow | 47.04 Cr | -120.15 Cr | -214.19 Cr | 18.79 Cr | — |
| Issuance Of Capital Stock | 0.00 | 99.99 Cr | — | — | — |
| Capital Expenditure | -75.53 Cr | -112.69 Cr | -187.60 Cr | -87.45 Cr | — |
| End Cash Position | 15.72 Cr | 1.14 Cr | 28.60 Cr | 11.61 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -1000.00 | -1000.00 | — | — | 1000.00 |
| Beginning Cash Position | 1.14 Cr | 28.60 Cr | 11.61 Cr | 6.20 Cr | — |
| Changes In Cash | 14.59 Cr | -27.47 Cr | 16.99 Cr | 5.41 Cr | — |
| Financing Cash Flow | -37.20 Cr | 82.38 Cr | 234.31 Cr | -6.24 Cr | — |
| Interest Paid Cff | -23.03 Cr | -14.68 Cr | -7.91 Cr | -4.81 Cr | — |
| Cash Dividends Paid | -1.00 Cr | -0.97 Cr | -1.04 Cr | -0.92 Cr | — |
| Net Common Stock Issuance | 0.00 | 99.99 Cr | — | — | — |
| Common Stock Issuance | 0.00 | 99.99 Cr | — | — | — |
| Net Issuance Payments Of Debt | -6.74 Cr | 5.51 Cr | 250.09 Cr | 5.89 Cr | — |
| Net Short Term Debt Issuance | -23.55 Cr | 42.34 Cr | 142.63 Cr | -6.08 Cr | — |
| Net Long Term Debt Issuance | 16.80 Cr | -36.84 Cr | 107.46 Cr | 11.97 Cr | — |
| Investing Cash Flow | -70.78 Cr | -102.39 Cr | -190.73 Cr | -94.59 Cr | — |
| Net Other Investing Changes | -0.95 Cr | 5.74 Cr | -3.37 Cr | -7.77 Cr | — |
| Interest Received Cfi | 0.93 Cr | 1.00 Cr | 0.99 Cr | 0.57 Cr | — |
| Dividends Received Cfi | 0.00 | 29000.00 | 5000.00 | 5000.00 | — |
| Net Business Purchase And Sale | 12000.00 | -1.00 Cr | — | — | — |
| Sale Of Business | 12000.00 | 0.00 | — | — | — |
| Purchase Of Business | 0.00 | -1.00 Cr | — | — | — |
| Net PPE Purchase And Sale | -70.76 Cr | -108.13 Cr | -187.57 Cr | -87.38 Cr | — |
| Purchase Of PPE | -75.53 Cr | -112.69 Cr | -187.60 Cr | -87.45 Cr | — |
| Operating Cash Flow | 122.57 Cr | -7.46 Cr | -26.59 Cr | 106.24 Cr | — |
| Taxes Refund Paid | -22.81 Cr | -27.04 Cr | -27.70 Cr | -33.06 Cr | — |
| Change In Working Capital | 7.55 Cr | -130.23 Cr | -135.25 Cr | -10.72 Cr | — |
| Change In Payable | 16.58 Cr | 40.04 Cr | -12.05 Cr | 33.64 Cr | — |
| Change In Inventory | -16.39 Cr | -17.02 Cr | -67.89 Cr | -21.16 Cr | — |
| Change In Receivables | 7.35 Cr | -153.24 Cr | -55.32 Cr | -23.19 Cr | — |
| Other Non Cash Items | 22.74 Cr | 14.83 Cr | 7.39 Cr | 4.32 Cr | — |
| Deferred Tax | 24.49 Cr | 29.54 Cr | 27.02 Cr | 31.00 Cr | — |
| Depreciation And Amortization | 21.06 Cr | 17.02 Cr | 22.28 Cr | 18.93 Cr | — |
| Depreciation | 21.06 Cr | 17.02 Cr | 22.03 Cr | 18.81 Cr | — |
| Gain Loss On Investment Securities | -0.12 Cr | -4000.00 | -5000.00 | -5000.00 | — |
| Gain Loss On Sale Of PPE | 0.00 | 2.30 Cr | -0.03 Cr | -0.07 Cr | — |
| Net Income From Continuing Operations | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Repayment Of Debt | — | -36.84 Cr | — | -6.08 Cr | -73.18 Cr |
| Issuance Of Debt | — | 42.34 Cr | 250.09 Cr | 11.97 Cr | 11.79 Cr |
| Net Other Financing Charges | — | -0.56 Cr | -0.22 Cr | -0.22 Cr | — |
| Short Term Debt Issuance | — | 42.34 Cr | 142.63 Cr | — | — |
| Long Term Debt Payments | — | -36.84 Cr | — | — | — |
| Net Investment Purchase And Sale | — | -1.00 Cr | -0.78 Cr | 0.00 | — |
| Purchase Of Investment | — | -1.00 Cr | -0.78 Cr | 0.00 | — |
| Long Term Debt Issuance | — | — | 107.46 Cr | 11.97 Cr | 11.79 Cr |
| Amortization Cash Flow | — | — | 0.25 Cr | 0.12 Cr | 0.11 Cr |
| Common Stock Dividend Paid | — | — | — | -0.92 Cr | -0.36 Cr |
| Short Term Debt Payments | — | — | — | -6.08 Cr | -73.18 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gufic Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.